Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 9/20 | 0.34 |
| ▸ | SLC6A2 known ✓ | P23975 | 8/20 | 0.34 |
| ▸ | HTR2A known ✓ | P28223 | 2/20 | 0.33 |
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.33 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.33 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.33 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.33 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.33 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 6/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4950381 | 0.82 | ALDH1A1 (0.44) | ALDH1A1TSHR | |
| SCHEMBL970597 | 0.78 | ALDH1A1 (0.54) | ALDH1A1TSHR | |
| SCHEMBL27694484 | 0.76 | ALDH1A1 (0.61) | ALDH1A1SLC6A4SLC6A2HTR2AADRB2 | |
| SCHEMBL8393350 | 0.75 | ALDH1A1 (0.42) | ALDH1A1TSHR | |
| SCHEMBL10454835 | 0.75 | SLC6A2 (0.37) | ALDH1A1SLC6A4SLC6A2ADRB2SLC6A3 | |
| Hydrochloric Acid SCHEMBL5473471 | 0.74 | ALDH1A1 (0.35) | ALDH1A1 | |
| SCHEMBL4867077 | 0.74 | SLC6A4 (0.44) | ALDH1A1SLC6A4SLC6A2HTR2AADRB2 | |
| SCHEMBL5478637 | 0.74 | ALDH1A1 (0.46) | ALDH1A1SLC6A4SLC6A2HTR2AADRB2 | |
| Hydrochloric Acid SCHEMBL27446814 | 0.73 | IRAK4 (0.39) | SLC6A4SLC6A2HTR2AADRB2HTR1A | |
| SCHEMBL27845256 | 0.72 | ALDH1A1 (0.35) | ALDH1A1SLC6A4SLC6A2ADRB2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137690-A1 | USE OF REBOXETINE TO TREAT NARCOLEPSY | AXSOME THERAPEUTICS INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-12616702-B2 | Use of reboxetine to treat narcolepsy | AXSOME THERAPEUTICS, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| US-20260097040-A1 | USE OF REBOXETINE TO TREAT NARCOLEPSY | AXSOME THERAPEUTICS INC (US) | 2026-04-09 | — | — | US | disclosed |
| US-20260041691-A1 | USE OF REBOXETINE TO TREAT NARCOLEPSY | AXSOME THERAPEUTICS INC (US) | 2026-02-12 | — | — | US | disclosed |
| US-20260014165-A1 | USE OF ESREBOXETINE TO TREAT NERVOUS SYSTEM DISORDERS SUCH AS FIBROMYALGIA | AXSOME THERAPEUTICS INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-20260014163-A1 | USE OF REBOXETINE TO TREAT FIBROMYALGIA | AXSOME THERAPEUTICS INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-20250360107-A1 | USE OF MAZINDOL TO TREAT NERVOUS SYSTEM DISORDERS | AXSOME THERAPEUTICS INC (US) | 2025-11-27 | — | — | US | disclosed |
| US-12447155-B2 | Use of reboxetine to treat narcolepsy | AXSOME THERAPEUTICS, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| EP-4598524-A1 | USE OF MAZINDOL TO TREAT NERVOUS SYSTEM DISORDERS | Axsome Therapeutics, Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| US-20250161316-A1 | USE OF REBOXETINE TO TREAT NARCOLEPSY | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-05-22 | — | — | US | disclosed |
| US-20070269516-A1 | Controlled release matrix | BIOAVAIL LABORATORIES INTERNATIONAL S.R.L. (BB) | 2007-11-22 | — | — | US | disclosed |
| US-7241805-B2 | For therapy of depressive condition | BIOVAIL LABORATORIES, INC. (CA) | 2007-07-10 | — | — | US | disclosed |
| US-20070027213-A1 | For therapy of depressive condition | BIOVAIL LABORATORIES INTERNATIONAL S.R.L. (CA) | 2007-02-01 | — | — | US | disclosed |
| WO-2007002597-A2 | MODIFIED-RELEASE FORMULATIONS OF A BUPROPION SALT | BIOVAIL LABORATORIES INTERNATIONAL S.R.L. (BB) | 2007-01-04 | — | — | WO | disclosed |
| US-7070806-B2 | Controlled release formulations coated with aqueous dispersions of acrylic polymers | PURDUE PHARMA LP (US) | 2006-07-04 | — | — | US | disclosed |
| US-20030198673-A1 | Controlled release formulations coated with aqueous dispersions of acrylic polymers | OSHLACK BENJAMIN (US) | 2003-10-23 | — | — | US | disclosed |
| US-6143353-A | HYDROPHOBIC, STORAGE STABILITY, | PURDUE PHARMA LP (US) | 2000-11-07 | — | — | US | disclosed |
| US-5639476-A | STABILITY | EURO-CELTIQUE, S.A. (LU) | 1997-06-17 | — | — | US | disclosed |
| US-5580578-A | SUSTAIN RELEASED BEADS COATED WITH A COPOLYMERS OF ACRYLIC AND METHACRYLIC ESTERS HAVING QUATERNARY AMMONIUM GROUP; STORAGE STABILITY, WATERPROOFING | EURO-CELTIQUE, S.A. (LU) | 1996-12-03 | — | — | US | disclosed |
| EP-0636366-A2 | Controlled release formulations coated with aqueous dispersions of acrylic polymers | Euroceltique S.A. (LU) | 1995-02-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250360107-A1 | USE OF MAZINDOL TO TREAT NERVOUS SYSTEM DISORDERS | PNMT, COMT, MAOA | SLC6A4 143/4885SLC6A2 69/4885HTR2A 38/4885 |
| US-20260014163-A1 | USE OF REBOXETINE TO TREAT FIBROMYALGIA | SLC6A4, SLC6A2, CRH | SLC6A4 1/4885SLC6A2 2/4885HTR2A 53/4885 |
| US-20030198673-A1 | Controlled release formulations coated with aqueous dispersions of acrylic polymers | ACR, PARG, AMPD1 | SLC6A4 2053/4885SLC6A2 3054/4885HTR2A 396/4885 |
| US-20260097040-A1 | USE OF REBOXETINE TO TREAT NARCOLEPSY | HTR2B, HCRTR2, HTR1B | SLC6A4 7/4885SLC6A2 5/4885HTR2A 12/4885 |
| US-12616702-B2 | Use of reboxetine to treat narcolepsy | SLC6A4, SLC6A2, SLC18A2 | SLC6A4 1/4885SLC6A2 2/4885HTR2A 40/4885 |
| US-20260137690-A1 | USE OF REBOXETINE TO TREAT NARCOLEPSY | SLC6A4, SLC6A2, SLC6A11 | SLC6A4 1/4885SLC6A2 2/4885HTR2A 55/4885 |
| US-20250161316-A1 | USE OF REBOXETINE TO TREAT NARCOLEPSY | HCRTR1, HCRTR2, AANAT | SLC6A4 5/4885SLC6A2 4/4885HTR2A 37/4885 |
| US-20260014165-A1 | USE OF ESREBOXETINE TO TREAT NERVOUS SYSTEM DISORDERS SUCH AS FIBROMYALGIA | FAAH, HTR2B, HTR5A | SLC6A4 5/4885SLC6A2 11/4885HTR2A 13/4885 |
| US-20070027213-A1 | For therapy of depressive condition | SLC6A2, SLC6A4, HTR5A | SLC6A4 2/4885SLC6A2 1/4885HTR2A 24/4885 |
| US-20070269516-A1 | Controlled release matrix | SLC6A2, SLC6A11, SLC6A1 | SLC6A4 4/4885SLC6A2 1/4885HTR2A 32/4885 |
| US-12447155-B2 | Use of reboxetine to treat narcolepsy | HCRTR1, HCRTR2, AANAT | SLC6A4 5/4885SLC6A2 4/4885HTR2A 37/4885 |
| US-20260041691-A1 | USE OF REBOXETINE TO TREAT NARCOLEPSY | SLC6A4, SLC6A2, MAPT | SLC6A4 1/4885SLC6A2 2/4885HTR2A 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.